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number of cell types in adult and embryonic mouse tissues. 
Furthermore, whilst SHIRPA testing revealed no behav-
ioural defects, we demonstrate increased trabecular mass 
in the long bones, confirming a role for OSTF1 in bone 
development.
Introduction
Osteoclast stimulation factor 1 (OSTF1) was originally 
described as SH3P2 in a screen for Src-homology 3 (SH3)-
containing proteins by peptide array (Sparks et al. 1996), 
and independently also discovered in an expression clon-
ing screen (Reddy et al. 1998). OSTF1 indirectly enhances, 
through the supernatant of transfected 293 cells, osteoclast 
formation and bone-resorption activity in cell culture assays. 
Structurally, OSTF1 is a small intracellular protein that 
contains an SH3 domain closely followed by four ankyrin 
domains (Tong et al. 2009). Northern blot analysis indicated 
the presence of a single OSTF1 transcript in multiple human 
tissues (Reddy et al. 1998). In a series of cell-based experi-
ments, overexpression of OSTF1 in HeLa cells was found to 
have a negative impact on cell motility in transwell migra-
tion assays (Tanimura et al. 2011). Morphologically, these 
transfected HeLa cells were found to be more rounded and 
had a smaller footprint that controls.
OSTF1 has been shown to interact directly with a series 
of intracellular proteins using several methods, includ-
ing co-immunoprecipitation, peptide array and yeast two 
hybrid. Binding partners identified include F-actin (Szym-
kiewicz et al. 2004), the non-receptor tyrosine kinase c-Src 
(Reddy et al. 1998; Szymkiewicz et al. 2004) and the E3 
ubiquitin-protein ligase Casitas B-lineage lymphoma (Cbl) 
(Szymkiewicz et al. 2004; Vinayagam et al. 2011). This spe-
cific interaction has been shown to be strengthened by the 
Abstract Osteoclast stimulation factor 1 (OSTF1) is an 
SH3-domain containing protein that was initially identified 
as a factor involved in the indirect activation of osteoclasts. 
It has been linked to spinal muscular atrophy in humans 
through its interaction with SMN1, and is one of six genes 
deleted in a human developmental microdeletion syndrome. 
To investigate the function of OSTF1, we generated an Ostf1 
knockout mouse model, with exons 3 and 4 of Ostf1 replaced 
by a LacZ orf. Extensive X-Gal staining was performed to 
examine the developmental and adult expression pattern, 
followed by phenotyping. We show widespread expres-
sion of the gene in the vasculature of most organs and in a 
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co-localisation of OSTF1 with Cbl in the podosomes of oste-
oclast-like cells, and has been suggested to be important for 
their bone-resorption properties (Szymkiewicz et al. 2004). 
OSTF1 has also been demonstrated to interact with Survival 
of Motor Neuron 1 and 2 (SMN1 and SMN2 respectively) 
(Kurihara et al. 2001; Vinayagam et al. 2011), the loss of 
which leads to spinal muscular atrophy. Both SMN1- and 
-2 are found in the cytoplasm of neurons from which they 
translocate to subnuclear bodies called gems, where small 
nuclear riboproteins are assembled (Massenet et al. 2002; 
Paushkin et al. 2002). Intriguingly, conditioned media from 
293 cells overexpressing SMN has also been shown to drive 
enhanced formation and hyper-activation of osteoclasts 
(Kurihara et al. 2001).
Together with three other known genes and two open 
reading frames of unknown functions, OSTF1 forms part 
of a chromosomal region that is deleted in a microdeletion 
syndrome at 9q21.13 (Baglietto et al. 2014; Boudry-Labis 
et al. 2013). The deletion leads to mild mental retardation, 
autism-spectrum disorder, small stature, speech delay and 
epileptic seizures. OSTF1 is thought to play only a minor 
role in this syndrome since the mouse knockout of two of 
the deleted genes, the retinoic acid receptor RAR-related 
Orphan Receptor B (RORB) and the magnesium channel 
Transient Receptor Potential cation channel, subfamily M, 
member 6 (TRPM6) recapitulate some of the syndrome’s 
phenotypes (Boudry-Labis et al. 2013). No knockout of the 
fourth gene in the deletion, Nicotinamide Riboside Kinase 
1 (NMRK1) has been reported.
Genome wide association studies correlate variation in 
OSTF1 to coronary artery diseases, variation in body mass 
index (Fox et al. 2007), Alzheimer’s disease (Furney et al. 
2011), multiple sclerosis (Baranzini et al. 2009) and non-
alcoholic fatty liver disease (Chalasani et al. 2010). How-
ever, correlation is not causation and the in vivo function of 
OSTF1 remains unknown.
Here, we report for the first time a mouse knockout for 
Ostf1, Ostf1lacZ/LacZ, where the coding exons 3 and 4 have 
been replaced by the LacZ reporter. We observe that the 
Ostf1lacZ/LacZ mouse suffers from a mild form of osteopetro-
sis, caused by an increase in trabecular bone. We have taken 
advantage of the LacZ insertion and extensively analysed 
the expression pattern of Ostf1 through X-Gal staining and 
defined further regions of potential interest for phenotyping.
Materials and methods
Accession IDs
Organism (mouse)—Taxon ID 10090.
Gene (Ostf1)—Gene ID 20409.
OSTF1+/LacZ mice
ES cells on the C57BL/6N background for the 
Ostf1 tm1(NCOM)Cmhd mouse, termed Ostf1LacZ line in 
this paper are available from NorCOMM under the ID 
NO1551. Chimeric mice were prepared by blastocyst 
microinjection and bred with C57BL/6J mice to obtain 
germline transmission. All experimental procedures using 
animals were approved by The University of Edinburgh’s 
Animal Welfare and Ethical Review Board and conducted 
under the Animals (Scientific Procedures) Act 1986. All 
work was performed under project licence #60/4424. All 
mice used in this study were euthanized by  CO2 inhalation.
Western blotting
Western blotting was done using standard procedures. 
The following primary antibodies were used: rabbit anti-
OSTF1 (Bethyl laboratories, A303-004A) at 1:10,000 dilu-
tion (Fig. 1a, g, f), rabbit anti-OSTF1 (Atlas HPA020514) 
at 1:200 dilution (Fig. 1b), rabbit anti-β actin (Neomarkers 
RB-9421-R1) at 1:100 dilution, rabbit anti-β galactosidase 
(Invitrogen A-11132) at 1:5000 dilution.
Fig. 1  The Ostf1LacZ/LacZ mouse is a knockout with β-galactosidase 
activity reflecting levels of Ostf1 expression. a Gene knockout strat-
egy: out of 10 exons (blue boxes), exons 3 and 4 are replaced by a 
LacZ Neo cassette (red). b Western blotting to detect endogenous 
OSTF1 in different tissues. OSTF1 protein expression is observed in 
wild-type kidney, liver, cortex and spine, but absent in Ostf1LacZ/LacZ 
tissues. β-galactosidase (LacZ) protein expression is only detected in 
Ostf1LacZ/LacZ tissues. β-actin was used as a loading control. c Expres-
sion of OSTF1 in lysates from MEFs derived from wild type (WT), 
Ostf1+/LacZ and Ostf1LacZ/LacZ mice. β-actin was used as a loading con-
trol
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Genotyping
DNA was extracted from fresh tissue, amplified by PCR 
and products resolved by gel electrophoresis. Primers used 
were: Exon 3F AAC CAC CAC TGT ATT CTA AGG TAG G, 
Exon 3R AAA CAG TCC AGC ACT ATG CTA ATC , Exon 4F 
CGG ACC CAG ATG GTT TCA G, Exon 4R CGT GCG TTT 
GTC CTG TTG , Exon 9F TTG TTC TCC GGT AGC TTT GC, 
Exon 9R CTC GCC CTT TGC AGT AAA AC, LacZ F ATC 
CTC TGC ATG GTC AGG TC, LacZ R CGT GGC CTG ATT 
CAT TCC . PCR conditions are available upon request.
LacZ staining
Otherwise mentioned, all products were obtained from 
Sigma. Tissues were processed for cryostat sectioning 
followed by X-Gal staining according to standard proce-
dures (Mackenzie et al. 1997). Some sections were coun-
terstained with eosin.
Generation of mouse embryonic fibroblasts (MEFs)
MEFs were generated from E13 embryos according to 
standard procedures and cultured in Optimem supple-
mented with 10% foetal bovine serum, penicillin/strep-
tomycin and 114 µM β-mercaptoethanol. After three pas-
sages, MEFS were processed either for X-Gal staining or 
for protein extraction.
Imaging
Stained sections were photographed with an upright AX10 
microscope (Zeiss) linked to a Retiga 400R camera (QIm-
aging) using a QImagin pluggin for ImageJ/FiJi. Images 
were processed and assembled using Adobe Photoshop. 
Some sections were photographed using a Dotslide scan-
ner (Olympus) and images were analysed using the OlyVia 
software (Olympus).
CT scanning and bone analysis
Legs of age-matched male WT and Ostf1lacZ/LacZ mice 
were isolated and fixed overnight in 4% paraformaldehyde. 
Muscles were then dissected out and the entire leg was 
stored in 70% ethanol. Scanning was performed on a Sky-
scan 1172 Micro-CT scanner (Bruker, Kontich, Belgium) 
following the protocol described in van’t Hof and Ralston 
(1997) and van’t Hof (2012). Data was then reconstructed 
and a slice of bone below the growth plate was selected for 
quantification as described in Idris et al. (2005).
Osteoclast differentiation
Legs of age-matched male WT and Ostf1lacZ/LacZ sibling 
mice were isolated. Bone marrow from tibia and femurs 
were expelled from bone shafts using a MEM-containing 
syringe and 23 gauge needle. Subsequently, bone marrow 
was triturated to dissociate the cells and then plated in MEM/
FCS/Pen-Strep/Glutamine containing macrophage colony 
stimulating factor (M-CSF, 100 ng/ml, Prospec) to induce 
macrophage production. After 2 days, M-CSF dependent 
macrophages were dissociated and 5000 cells were put in 
each well of a Lab-Tek multichamber. Medium was then 
changed to MEM/FCS/Pen-Strep/Glutamine containing 
25 ng/ml of M-CSF and 100 ng/ml of Receptor activator of 
nuclear factor kappa-B ligand (RANKL, Prospec) to induce 
osteoclast differentiation. Cells were left to differentiate for 
5 days before processing.
Tartrate resistant acid phosphatase (TRAP) staining
Fixed osteoclast cultures were TRAP stained according to 
protocol described in (Idris et al. 2005). Chamber slides 
containing osteoclasts were photographed with an inverted 
microscope (Zeiss) and multinucleate TRAP-positive osteo-
clasts were manually counted.
Identification of OSTF1‑interacting proteins
To identify OSTF1-interacting proteins, HEK293 cells cul-
tured in DMEM/10% FCS/Pen-Strep were transiently trans-
fected in triplicate with either empty vector (pCDNA3.1 
V5-His) or V5-OSTF1 plasmids. After 48 h, cells were lysed 
in IP lysis buffer (50 mM Tris pH 7.5, 1% Triton-X100, 
150 mM NaCl), protein content measured and subjected to 
automated IP on a Kingfisher Duo (Thermo) using anti-V5 
magnetic agarose (MBL). Digestion and protein identifica-
tion was performed by the MRC Institute of Genetics & 
Molecular Medicine Proteomics Facility.
Behaviour analysis
Mice tested were age-matched siblings from heterozygotous 
pairing. Cohorts consisted of six female WT, seven female 
heterozygotes and six female Ostf1LacZ/LacZ, four male WT, 
three male heterozygotes and eight male Ostf1LacZ/LacZ.
1. SHIRPA test was as described in Rogers et al. (1997)
2. Cat Box test: In order to analyse movement and gait, 
we constructed a 1 m-long, 10 cm wide and 20 cm high 
Perspex box with a translucent floor located mid-height, 
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Fig. 2  OSTF1 is widely 
expressed in brain tissue. a 
Tissues belonging to the nerv-
ous system were dissected and 
subjected to western blotting 
using an anti-OSTF1 antibody 
with β-actin serving as loading 
control. RPE retinal pigmented 
epithelium. b The parabrachial 
nucleus expresses the highest 
level of OSTF1 (arrow). c–g 
OSTF1 is found at low level 
in the hippocampal formation. 
d OSTF1 expression appears 
as puncta in the subiculum. 
e OSTF1 expression in the 
polymorph layer of the dentate 
gyrus (DG). f, g The cornus 
amonis (CA) region 2 (CA2) 
defined by dashed lines between 
CA1 and CA3. h, i In the cortex 
of the cerebellum (panel h), 
OSTF1 is only found in blood 
vessels (arrowhead) but it is 
consistently present in the 
deep cerebellar nuclei (panel 
i—arrow). j, k Small puncta 
indicate low levels of expres-
sion in the mammillary nucleus 
(panel j—arrow) and the 
spinal vestibular nucleus (panel 
k—arrow). k The ventricular 
surface (white arrow) and the 
choroid plexus (red arrow) both 
express OSTF1. l, m Through-
out the brain, OSTF1 is highly 
expressed by the endothelium 
of the blood vessels (black 
arrowheads) as exemplified by 
large and small blood vessels in 
panel k, l and in small branched 
cells. n, p In the E14 embryo 
head, OSTF1 expression was 
observed in the blood vessels 
and the meninges (dark arrow-
heads). n OSTF1 is, however, 
also present in the cartilage 
precursor of the skull (arrows). 
o At this stage, the trigeminal 
neurons express varying levels 
of OSTF1. p In contrast, the 
spiral ganglia express high 
levels of OSTF1 and the epithe-
lium of the cochlear epithelium 
(notched arrowhead). Scale bar 
= 500 µm, all other panels scale 
bar = 100 µm
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10 cm from the base. A 45° angle mirror was placed 
under the floor so that the mouse could be observed 
from the side and from underneath at the same time. 
Mice were allowed to run the length of the box to a card-
board tube while being filmed using a Canon S500 SLR 
camera. Movies were converted to the AVI format using 
Avidemux (http://www.avidemux.org/admWiki/doku.
php) before being imported into ImageJ/Fiji (Schneider 
et al. 2012). A custom macro was then used to record the 
positions at which each paw made contact with the floor. 
Step size was measured using Pythagoras’ theorem.
3. Food burrowing test was as described in Yang and Craw-
ley (2009)
4. Preyer’s reflex: We have constructed a click box (https://
www.ihr.mrc.ac.uk/projects/clickBox). Preyer’s reflex 
was tested by clicking once near the tested animal and 
observing whether its ears twitched.
Results
Ostf1LacZ/LacZ is a knockout for Ostf1
We took advantage of the availability of an Ostf1 mouse 
ES cells, Ostf1LacZ/LacZ, from the North American Condi-
tional Mouse Mutagenesis Project (Fig. 1a). In these mice, 
exons 3 and 4 that encode most of the Ostf1 SH3 domain 
are replaced by a LacZ expression cassette. As a result, the 
remaining exons are out of frame. As expected, OSTF1 
protein was undetectable by Western blotting in Ostf1lacZ/
LacZ tissues (Fig. 1b). Instead, LacZ was expressed under 
Table 1  Table summarising 
expression pattern of OSTF1 in 
the adult mouse brain
Main structure Structure Level of 
expres-
sion
Everywhere Blood vessels 3
Pial surface 2
Cortex Somatosensory, layer V 1
Hippocampal formation CA2 1
Polymorph region of dentate gyrus 1
Subiculum 1
Thalamus Submedial nucleus of the thalamus 1
Reticular nucleus of the thalamus 1
Mediodorsal nucleus of the thalamus 1
Hypothalamus Mammillary nucleus 1
Striatum Amygdalar nuclei 1
Midbrain Red nucleus 1
Oculomotor nucleus 1
Cerebellum Deep cerebellar nuclei 1
Hindbrain Pontine gray 1
Pontine reticular nucleus 1
Superior olivary complex 1
Tegmental reticular nucleus 1
Dorsal nucleus raphe 3
Medial vestibular nucleus 1
Dorsal cochlear nucleus 1
Nucleus of the lateral lemniscus 1
Primary sensory nucleus of the trigeminal 1
Spinal vestibular nucleus 1
Paragigantocellular reticular nucleus 2
Spinal cord Motor neurons 1
Floor plate 1
Central canal 1
DRGs Salt and pepper in all sensory neurons 2–3
Cranial ganglia Trigeminal 3
Vestibulocochlear ganglia 3
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the control of Ostf1 promoter (Fig. 1b). Similarly, reduction 
and loss of OSTF1 protein was also observed in embryonic 
fibroblasts derived from Ostf1+/LacZ and Ostf1lacZ/LacZ ani-
mals, respectively (Fig. 1c).
Heterozygous mating yielded 151 mice at the ratio of, 40 
wild types: 63 heterozygotes: 48 knockouts. Both male and 
female homozygous Ostf1lacZ/LacZ mice were fertile and with-
out overt deleterious phenotype up until the age of 1 year.
Ostf1 expression
In order to define potential function of the Ostf1, the spatial 
and temporal pattern of expression was examined through 
the use of a combination of X-Gal staining, Western blotting 
and RT-PCR. X-Gal staining was used extensively since it 
allows for resolution of expression at the single cell level.
Central nervous system
Unlike the recently assumed (Baglietto et al. 2014; Boudry-
Labis et al. 2013) and in keeping with the original findings 
of Reddy et al. (1998), we find that Ostf1 is widely expressed 
in the brain, albeit at low levels. Western blotting revealed 
Ostf1 expression in virtually all central nervous system 
regions’ analyses, albeit at differing levels (Fig. 2a). Results 
are summarised in Table 1. The highest level of expres-
sion was noted in the neurons of the parabrachial nucleus 
(Fig. 2b, arrow). Together with axons from the cranial gan-
glia, the parabrachial nucleus neurons were the only ones 
to sport neurites that were also clearly labelled. In other 
regions, LacZ was expressed far more weakly, suggest-
ing that less Ostf1 is normally expressed. For example, we 
observed Ostf1 expression in the hippocampal formation 
(Fig. 2c): in the subiculum (Fig. 2d, arrows), polymorph 
region of the dentate gyrus (Fig. 2e, DG, arrow), Cornus 
Amonis region 2 (CA2) (Fig. 2g, arrow, defined by dashed 
line) but neither CA1 or CA3 (Fig. 2f, g). In the cerebellum, 
Ostf1 was restricted to blood vessels in the cortex (Fig. 2h, 
black arrow head) and it was observed as small puncta in the 
neurons of the deep cerebellar nuclei (Fig. 2i, arrow). Ostf1 
was also expressed in the mammilary nucleus and the spinal 
vestibular nucleus (Fig. 2j, k respectively).
Fig. 3  OSTF1 is widely expressed in the spinal cord and dorsal 
root ganglia (DRGs). a–c At E10, OSTF1 is found exclusively in 
the developing capillary network of the spine (panel a), surrounding 
OSFT1-negative DRGS (panel b) and motor neurons (panel c, Mn). 
d–h Strong expression in the blood vessels (bv and dark arrowheads) 
at E15. The neurons of the DRGs start expressing OSTF1 (panel e) at 
E15. It is at that stage that motor neurons (panel f) begin expressing 
OSTF1. g The floor plate (FP) but not the central canal (cc) express 
OSTF1. h The cartilage surrounding the spine expresses low levels 
of OSTF1. i–m Expression in the blood vessels (bv and dark arrow-
heads) in adult mice. i, j In the adult mouse, all DRG neurons express 
OSTF1, albeit at different levels, the signal is not restricted to the 
cell bodies and can be found in the neurites (n) of the dorsal roots to 
the Dorsal Root Entry Zone (DREZ) and the distal part of the dor-
sal funiculus (arrow in panel i, df) as well as at the Motor Exit Point 
(MEP). k Expression of OSTF1 in the motor neurons (arrows) is well 
established. l Likewise, OSTF1 is found in the central canal (cc). m 
Low level of OSTF1 is detected in the sympathetic ganglia (SG). 
Scale bars = 100 µm
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Throughout the brain, large and also small blood ves-
sels were strongly labelled (dark arrowheads exemplified 
in Fig. 2l, m). Likewise, the lining of the brain, the ventri-
cles as well as the choroid plexus (Fig. 2l, white and red 
arrows) were LacZ positive. Finally, everywhere except in 
the cerebellum, small branched cells, presumably oligoden-
drocytes and their precursors were observed to express Ostf1 
(Fig. 2m).
In the spinal cord as in the brain, the capillary network 
was strongly LacZ positive as early as at E11, (Fig. 3a–c, 
arrowheads), at E14 and in adult tissues (Fig. 3d, i respec-
tively). Noticeably, motor neurons expressed low levels of 
Ostf1 from E14 until adulthood (Fig. 3b, e, k, arrows). At 
E14, the floor plate was observed to express low levels of 
Ostf1 (Fig. 3g, FP) but this was no longer seen in the adult. 
In contrast, in the adult spine, the ependymal cells of the 
central canal were also LacZ positive (Fig. 3l, cc), while 
these structures were not LacZ positive in E14 and E11 
spines (Fig. 3g, cc).
Peripheral nervous system
Both trigeminal ganglia (Fig. 2o, arrow) and spiral ganglia 
(Fig. 2p, arrow) expressed high levels of OSTF1. While all 
the neurons of the spiral ganglia were LacZ positive at E14, 
expression was initially non-uniform in trigeminal neu-
rons. In contrast, in the adult mouse, all neurons strongly 
expressed LacZ.
LacZ was detected in the sensory neurons of the Dorsal 
Root Ganglia (DRGs) from E14 onwards (Fig. 3a, b, d, 
e, respectively) when DRGS were composed of neurons 
expressing no, weak or strong OSTF1 expression. In adult 
DRGs, all neurons express Ostf1 to some degree (Fig. 3i, 
j), indicating that Ostf1 expression varies between dif-
ferent types of sensory neuron and their developmental 
stage. This was further supported by the mixture of LacZ 
positive and negative axons present in sensory nerves 
(Fig. 3J, n) near the DRGs and at Dorsal Root Entry Zone 
(DREZ) level (Fig. 3i, DREZ). Given the lateral position 
of the LacZ positive axon bundles in the dorsal funiculus 
(df), it appears likely that the DRG neurons which express 
high levels of Ostf1 are nociceptors (Fig. 3i, arrow). In 
contrast, Ostf1 signal in the sympathetic ganglia (Fig. 3m, 
Fig. 4  OSTF1 is expressed in the eye. a–d LacZ stained flat 
mounted retina indicate OSTF1 is scattered on the retina surface. b, 
c Isolectin-B4 staining (white in panel b, c) does not colocalise with 
OSTF1, suggesting that the retinal blood vessels (BV) do not express 
OSTF1. c, d OSTF1 is found concentrated, in the ganglia cell layer, 
around cells with large nuclei (stained with DAPI) and cytoplasm 
(arrow), presumably G1 cells. e In transverse section of the retina 
of an  OSTF1LacZ/LacZ albino mouse, OSTF1 is found in the ganglia 
cell layer (GCL), the outer plexiform layer (OPL) and the retinal pig-
mented epithelium (RPE) but not the inner plexiform layer (IPL), 
inner nuclear layer (INL), outer nuclear layer (ONL), inner (IS) and 
outer segments (OS) of the photoreceptors, choroid and sclera. f Mul-
ler glial cells (arrow) express OSTF1. g The outer cells of the cornea 
express OSTF1. h, i In the embryo and P6 pup, OSTF1 is found in the 
capillary network (arrows) and can be counterstained with isolectin 
B4 (white in panel i). All scale bars = 50 µm
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SG) was weak, diffuse, and similar to that seen in the 
motor nerves at the Motor Exit Point (MEP, Fig. 3i), sug-
gestive of a glial origin.
Sensory organs—ear and eye
In the ear, Ostf1 was observed in the cochlear epithelium in 
the embryo (Fig. 2p, notched blue arrowhead) and also the 
adult (data not shown). Ostf1 signal in the eye appears to be 
restricted to the retina. Striking differences in expression 
were observed between the developing and mature struc-
tures. In the developing eye and up until early postnatal 
stages when the retinal vasculature is completely remod-
elled (Pitulescu et al. 2010), Ostf1 was exclusively found in 
the blood vessels (Fig. 4h, i). In contrast, in the adult retina, 
Ostf1 was excluded from blood vessel networks lining the 
ganglia cell layer (Fig. 4a–d) and instead restricted to spe-
cific deeper layers (Fig. 4e, f) as well as outer layers of the 
Fig. 5  OSTF1 is expressed in 
lung and liver tissues. a In adult 
lung, OSTF1 is expressed in the 
alveolar parenchyma (Alv), the 
epithelium of bronchus (Br) and 
terminal bronchus (TBr) and 
blood vessel endothelium (Bv). 
b In embryonic lung (E15), 
OSTF1 is detected in the devel-
oping capillary network, but not 
in the bronchus (arrowhead). c 
In embryonic liver (E15), we 
find OSTF1 expression in dis-
tinct cells spread in the paren-
chyme, likely to be hematopoi-
etic stem cells. d In contrast, in 
the adult liver, OSTF1 is found 
exclusively in endothelial cells 
in a low-to high gradient from 
the hepatic zone 1 surrounding 
the portal vein (PV) to zone 3 
around the central vein (CV). 
Scale bars = 100 µm
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cornea (Fig. 4g). Flat mounting of the retina revealed Ostf1 
expression on the eye’s inner surface was present in the gan-
glia cell layer (GCL, Fig. 4a, b). However, some signal was 
clustered around a few cells (Fig. 4c, arrow). Judging by 
their larger nuclei and somata (Fig. 4d, arrow), these were 
possibly G1 cells (Volgyi et al. 2009). In transverse section 
(Fig. 4e, f), LacZ was detected in GCL, in the outer plexi-
form layer (OPL), where horizontal cells reside, and in the 
retinal pigmented epithelium (RPE). In a few sections, we 
observed large columnar LacZ positive Muller glial cells 
connecting the GCL with the border between outer nuclear 
layer (ONL) and photoreceptor inner segment (IS) (Fig. 4f, 
arrow).
Lung
X-Gal staining shows Ostf1 expression in the embryonic 
lung at E14 and in the adult tissue. In adult lung, Ostf1 
appears ubiquitous in the respiratory epithelium of the 
alveolar parenchyme (Fig. 5a, Alv). It is also found in the 
epithelium of the bronchi (Br) and of the terminal bronchi 
(TBrl). As in most tissues, OSTF1 is found in the endothelial 
cells of blood vessels (Bv), according to vessel morphol-
ogy both arterioles and venules. In contrast, in the embryo, 
Ostf1 localises to the growing network of blood vessels but 
is excluded from the bronchi (Fig. 5b, arrow).
Liver
Expression of Ostf1 changes dramatically between embry-
onic and adult liver (Fig. 5c, d). In the embryo, Ostf1 is 
strongly expressed in cells scattered around the liver 
(Fig. 5c, arrows), which may represent hematopoietic stem 
cells, but it is absent from the remainder of the organ. In 
contrast, in adult liver, Ostf1 is absent from the hepatocyte 
cordons, but strongly expressed in the sinusoidal endothelial 
cells that surround the central veins (Fig. 5d, dashed lines, 
Cv). Interestingly, compared to the area surrounding the 
central vein, Ostf1 expression surrounding the portal vein is 
weaker and limited to a subset of endothelial cells (Fig. 5d, 
PV). This is suggestive of a gradient from low-to-high Ostf1 
expression from hepatic acinus zone 1–3, which is accom-
panying blood flow.
Heart
In the adult heart, Ostf1 was found to be expressed in the 
endothelium of the atrium (Fig. 6a, red arrowhead in At) 
and the vasa vasorum of the ventricle (Fig. 6a, Vv, black 
arrowheads and Vent) but surprisingly it was not found lin-
ing the inside of the ventricles (data not shown). Some heart 
myocytes and pericardial cells expressed low levels of Ostf1 
as seen by small X-Gal puncta (Fig. 6a). In embryonic heart 
at E14, Ostf1 was found to be expressed at the surface of 
the lips of the aortic valve (Fig. 6b, c, Av), as well as the 
endothelium of the aorta (Fig. 6b, Ao).
Kidney
Ostf1 was widely expressed in the kidney, from cortex 
to ureter (Fig. 7a). In the cortex, Ostf1 was found in the 
glomeruli (Fig. 7b, Gl) and associated blood vessels and 
the proximal convoluted tubule. In the medulla (Fig. 7c), 
Ostf1 was found to be expressed to varying degrees in all 
tubules, with highest expression in the proximal convoluted 
tubules. In both regions, blood vessels were LacZ positive 
(Fig. 7d) both in the endothelium and also in the underly-
ing smooth muscle rings. The renal papilla clearly exhibited 
the highest level of Ostf1expression in the kidney (Fig. 7a, 
e). Kidney Ostf1 expression clearly begins early with LacZ 
being detected throughout the kidney at P0 except for the 
outer nephrogenic zone (Fig. 7f) and in blood vessels of the 
developing organ at E14 (Fig. 7g). Ostf1 expression was 
markedly absent from the adrenal glands at this timepoint 
(Fig. 7f, asterisks).
Fig. 6  OSTF1 is expressed in the adult and embryonic heart. a In 
the adult heart, OSTF1 is found in the endothelium (red arrow) of 
the atrium (At), the large (Vv) and small vessels (arrowheads) that 
form the vasa vasorum of the ventricle (Vent). Small puncta indicate 
that the cardiomyocytes also express OSTF1. b, c In embryos, OSTF1 
expression is seen in the aortic valves (Av) and the endothelium of 
the aorta (Ao) but not in the cardiac endothelium itself. Scale bars = 
100 µm
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Fig. 7  OSTF1 is highly 
expressed in the kidney. a 
Transverse section through 
adult kidney demonstrates that 
OSTF1 is expressed in the cor-
tex (Ctx), Medulla (Med), blood 
vessels (Bv), calyx (Cx) and 
Ureter but not in the underlying 
adipose tissue. b In the cortical 
region, OSTF1 is found in the 
glomeruli (Gl) and the proximal 
convoluted tubules. c OSTF1 
is expressed at varying levels 
in all tubules of the medulla. d 
Renal arteries express OSTF1 in 
the endothelium and underly-
ing smooth muscle. e The 
ureter wall expresses OSTF1 
in a mosaic of high expression 
patches surrounded by low 
expression. f Whole mount 
expression in the P0 kidney 
shows wide expression in the 
kidneys and ureter (arrowhead) 
but not the adrenal glands (*). 
g In the embryonic kidney, 
OSTF1 is exclusively confined 
to the developing capillary net-
work. Scale bars = 100 µm
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Placenta
All the embryo-derived parts of the E14 placenta were found 
to be LacZ positive (Fig. 8a, b); this applied particularly 
to the labyrinth and spongiotrophoblast (Fig. 8b, Lab and 
Sp). This may in part be due to the large amount of vascu-
lature in that region. In the umbilical cord, the highest level 
of expression was observed in the endothelial lining of the 
blood vessels (Fig. 9c, Bv), but no expression was found in 
the underlying gut structure (Fig. 9c, gut).
Expression in bone tissue
Given that OSTF1 is thought to impact osteoclast activity 
(Reddy et al. 1998), its identification in bones was seen as 
a priority. In embryonic tissue, the pre-existing cartilage 
matrix that will develop into bone was only LacZ positive 
in Ostf1+/LacZ and Ostf1LacZ/LacZ embryos (Fig. 3k, Cart; 
Fig. 2n, arrows pointing to lower jaw and facial bone primor-
dium), but not their wild-type siblings, suggestive of Ostf1 
expression in bone. More developed bone tissues harbour 
endogenous beta-galactosidase-like activity, in particular in 
osteoclasts (Kopp et al. 2007), making it problematic to draw 
conclusion from X-Gal staining of developing or indeed 
established bones. We, therefore, performed semi-quantita-
tive RT-PCR of cultured osteoclast and osteoblasts as they 
differentiated from bone marrow to identify whether they 
expressed Ostf1. Ostf1 expression was detected at all stages 
of differentiation of both cell types. However, while Ostf1 
appeared to be evenly expressed in osteoclasts throughout 
differentiation, its expression in osteoblasts decreased over 
time (Fig. 10a, b).
Phenotyping of the Ostf1LacZ/LacZ mouse
We have generated a mouse that is knocked out for Ostf1. In 
absence of any clear developmental phenotype, and in order 
to define where, when and what could be perturbed by loss 
of Ostf1 expression, we have characterised the expression 
of Ostf1 in embryonic and adult mouse. In parallel to the 
LacZ staining, we have analysed the histology of the various 
tissues analysed by routine haematoxylin and eosin staining 
and observed no significant histological abnormalities. It is, 
however, possible that the physical or functional abnormali-
ties may not show up by simple histology.
Bone phenotyping
OSTF1 was first described as an indirect osteoclast stimu-
lating factor. We, therefore, compared the differentiation of 
Ostf1LacZ/LacZ osteoclasts with wild-type controls. Follow-
ing differentiation in vitro, primary bone marrow-derived 
osteoclasts were stained for Tartrate Resistant Acid Phos-
phatase (TRAP) to permit quantitation of osteoclast dif-
ferentiation. No difference was observed in the ability of 
primary bone marrow-derived macrophages to differentiate 
into TRAP-positive osteoclasts between wild-type (400.5/
Well, SEM 32.1, Fig. 9c) and Ostf1LacZ/LacZ (447/well, SEM 
15.7, p = 0.21) cultures. Thus, OSTF1 is not required for 
osteoclast differentiation in vitro.
We next investigated whether loss of Ostf1 might impact 
on osteoclast activity, and analysed bone density by micro-
CT scanning, focussing on tibiae and femurs of age-matched 
knockout and wild-type male mice (15 weeks; n = 8 WT, 
6 KOs, both legs scanned). This method, which relies on 
X-ray imaging of a rotating bone, reveals the fine trabecular 
bridges located under the growth plate without destroying 
the bone. Images were reconstructed and a volume of inter-
est located just under the growth plate was computationally 
analysed for bone volume, density and surface (Fig. 9d). 
Fig. 8  OSTF1 is expressed throughout the embryonic placenta and 
the umbilical cord. a Low magnification view of the placenta of an 
Ostf1LacZ/LacZ embryo implanted in the uterine wall of its Ostf1+/LacZ 
mother. b All tissues of embryonic origin express high levels of 
OSTF1, specially the spongiotrophoblast layer (Sp) and the labyrinth 
layer (Lab). The glycogen cells also express high levels of OSTF1 
while less is found in the maternal decidua (Md) and none in the 
myometrium (Myo). There is high level of expression in the mesoder-
mal cells of the yolk sac (Mes). c In the umbilical cord, there is high 
level of expression in the blood vessels (bv) but none in the gut. Scale 
bar a = 500 µm, scale bars in b, c = 100 µm
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This revealed that Ostf1LacZ/LacZ tibia and femur were sig-
nificantly denser than wild-type counterparts. Normalised 
to wild type, the Ostf1LacZ/LacZ bone volume/tissue volume 
(BV/TV) was 122% (SEM 6.5%, p < 0.01) for the femur and 
118.43% (SEM 2.33%, p < 0.01) for the tibia. Whilst trabec-
ular thickness of WT and Ostf1LacZ/LacZ bones was indistin-
guishable, the trabecular number was increased in Ostf1LacZ/
LacZ to 122.52% (SEM 5.49%, p < 0.01) in the femur and to 
115.41% (SEM 2.31%, p < 0.01) in the tibia (Fig. 9e, f and 
Supplemental Fig. 2). We concluded that loss of OSTF1 con-
fers mild osteopetrosis-like phenotype caused by an increase 
in trabecular number but not thickness.
OSTF1 interacting proteins
In order to understand how OSTF1 might influence bone 
density, a proteomic approach was used to identify OSTF1-
interacting proteins in HEK293 cells, the cell line which was 
first used to demonstrate that OSTF1 stimulated secretion 
of a factor/s that promoted osteoclast differentiation (Reddy 
et al. 1998). HEK293 cells were transfected in triplicate with 
either empty vector (Vector) or a vector encoding human 
OSTF1 tagged at the N-terminus with a V5-epitope tag 
(V5-OSTF). Cell lysates were then subjected to V5 immu-
noprecipitation and co-immunoprecipitating proteins identi-
fied by LC-MS/MS.
Fig. 9  RT PCRs indicate OSTF1 is expressed in osteoclasts and oste-
oblasts and its loss leads to increased bone density. a Ostf1 mRNA 
is detected in differentiating osteoclast cells from primary bone 
marrow-derived macrophages at day 0 until fully differentiated at 
day 5. GAPDH was used as a positive control. b Ostf1 mRNA is also 
expressed throughout osteoblasts differentiation. TBP was used as a 
positive control. c Loss of Ostf1 expression does not perturb osteo-
clast differentiation. Equal numbers of primary bone marrow-derived 
macrophages from wild type and (WT) Ostf1LacZ/LacZ (KO) male mice 
were plated and differentiated to osteoclast in  vitro (n = 3 for each 
genotype). Mature osteoclasts were identified and quantified follow-
ing TRAP staining (n.s. not significant). d Micro-CT scanning pro-
cedure from bone scanning to selection of trabecular bone for analy-
sis. e Femurs from adult male Ostf1LacZ/LacZ mice (n = 14) exhibit 
elevated bone density (BV/TV p ≤ 0.01, asterisk) and trabecular num-
ber (Tb.N p ≤ 0.01, asterisk) compared to wild type (WT—n = 16) as 
ascertained by µCT scanning. No difference in trabecular thickness 
(Tb.Th p > 0.2, n.s. not significant) was observed. f Tibia from adult 
male Ostf1LacZ/LacZ mice (n = 12) exhibit elevated bone density (BV/
TV p < 0.01, asterisk) and trabecular number (Tb.N p < 0.01, asterisk) 
compared to wild type (WT—n = 16) as ascertained by µCT scan-
ning. No difference in trabecular thickness (Tb.Th p > 0.2, n.s. not 
significant) was observed
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This approach identified 18 proteins that were sig-
nificantly enriched (p < 0.05) in IPs from cells express-
ing V5-OSTF1 compared to vector control (Fig.  10a; 
Table 2). This list contained both cytosolic and nuclear-
localised proteins which were reflected by the subcellular 
localisation of V5-OSTF1 in transfected HEK293 cells. 
Immunofluorescence demonstrated V5-OSTF1 to be 
localised to the cytosol, the golgi and the nucleus, but 
excluded from regions of dense chromatin (Fig. 10b). 
Reassuringly, the top interacting protein was Myosin 
1e, which has been previously identified to interact with 
OSTF1, and is thought to regulate cytoskeletal reorgani-
sation and vesicular trafficking (Tanimura et al. 2016). 
Interestingly, Myosin 1e has also been demonstrated to 
regulate secretion of the chemokine CCL2, deficiency 
of which causes increased bone mass in mice (Sul et al. 
2012; Wenzel et al. 2015). An additional OSTF1-inter-
acting protein was found to be AP3D1, a subunit of the 
golgi-localised AP3 vesicular trafficking complex, dis-
ruption of which leads to dysregulation of peptide hor-
mone release in mice (Sirkis et al. 2013). The majority 
of the remaining interacting proteins are associated with 
nuclear functions including RNA splicing, chromatin 
remodelling and gene expression (Table 2). A notable 
absence was SMN1, although this may reflect the cell 
type used in the immunoprecipitation experiment. How-
ever, many of the OSTF1-interacting proteins identified 
function in RNA splicing, where SMN1 facilitates the 
assembly of snRNP spliceosome components.
Behaviour phenotyping
Although we did not identify SMN as an OSTF-interacting 
protein in HEK293 cells, this interaction may still occur in 
other cell types such as motor neurons. OSTF1 was previ-
ously reported to interact with SMN (Kurihara et al. 2001), 
loss of SMN impacts bone development (Shanmugarajan 
et al. 2007) and SMN is expressed by osteoclasts (Kurihara 
et al. 2001), we wondered if the Ostf1LacZ/LacZ would share 
phenotypes seen in SMN mutant mice. SMN knockout mice 
are embryonic lethal (Schrank et al. 1997) and hypomorphs 
suffer from muscle weakness that inversely correlates with 
the level of SMN expression (Edens et al. 2015; Lefebvre 
et al. 1997). This is clearly not the case of the Ostf1 mice 
which live up to a year without obvious phenotype but it was 
still possible that Ostf1 mice behave abnormally.
As many of the OSTF1-interacting proteins (Table 2) 
result in neurological defects and human microdeletion 
patients where the OSTF1 gene is one of six deleted genes 
also display neurological abnormalities, Ostf1 mice were 
rigorously examined via a SHIRPA protocol, a battery of 
non-intrusive tests where mice are observed mostly unchal-
lenged (Rogers et al. 1997). These tests are designed to 
monitor neuropsychiatric, cerebellar and sensory functions 
together with muscle function. Ostf1LacZ/LacZ mice had nor-
mal SHIRPA score (Fig. 11a). Part of the SHIRPA protocol 
involves balance and coordination tests where mice are put 
on a grid, the grid is suddenly inverted and lightly shaken 
Fig. 10  Identification of OSTF1-interacting proteins. a Volcano 
plot showing proteins identified by LC-MS/MS that are enriched in 
V5-OSTF1 IPs. HEK293 cells were transiently transfected in tripli-
cate with empty vector or V5-OSTF1. Lysates were subjected to V5 
IP and co-immunoprecipitating proteins identified by LC-MS/MS. 
X-axis shows average fold enrichment of individual proteins (blue 
points) in cells expressing V5-OSTF1 compared to empty vector. 
Y axis shows p value. Dashed red line represents p = 0.05 cutoff. b 
OSTF1 localises to the cytosol, nucleus and golgi. V5-OSTF1 was 
transiently transfected into HEK293 cells, and cells were fixed, per-
meabilised and immunostained with anti-V5 antibody (green), anti-
GM130 (red) to stain the golgi, and DAPI (blue) to label the nucleus. 
Scale bar = 10 µm
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and time taken for mice to release their grip recorded. The 
Ostf1LacZ/LacZ cohort showed no difference than control sib-
lings (Fig. 11b). Next, gait of wild type and mutant mice 
were examined using a cat walk box, a transparent box with 
a translucent bottom where paw position can be observed 
(Fig. 11c). Mice were filmed running for one metre towards 
the relative shade of an empty cardboard tube. Movies were 
analysed by recording paw print using a custom imageJ plug-
in. Each paw strike gave a coordinate that could then be 
plotted (Fig. 11d) and from which step size was calculated. 
Thus, plotting against frame allows analysis of paw strike 
synchrony (Fig. 11e), and plotting against step allows to see 
if the run is regular (Fig. 11f). Finally, by averaging the step 
for each paw for each animal, it was possible to see if there 
Table 2  Table showing the identity, function, disease association, fold enrichment and p value of proteins identified as co-immunoprecipitating 
with V5-OSTF1 from HEK293 cells
Gene symbol Full name Function Disease associations Log2 fold 
enrich-
ment
Actual fold 
enrichment
p Value
OSTF1 Osteoclast stimulation 
factor 1
Cytoskeleton Deleted in microdeletion 
sydrome with epilepsy 
and intellectual disability
10.4 1391.1 0.003478529
MYO1E Myosin 1E Vesicular trafficking; actin 
reorganisation
Mutated in focal segmental 
glomerulosclerosis-6
10.4 1319.5 0.000231218
SLU7 SLU7 homolog RNA splicing 7.6 196.2 0.023058311
AP3D1 Adaptor-related protein 
complex 3, delta-1 subuint
Vesicular trafficking Mutated in Hermansky-
Pudlak syndrome and 
"mocha" mose model
5.9 58.1 0.024118142
ACIN1 Apoptotic chromatin con-
densation inducer 1
Apoptotic chromatin con-
densation; RNA splicing
5.9 58.1 0.038838599
GTPBP4 GTP-binding protein 4 Unknown 5.7 52.6 0.005445883
TOP2B Topoisomerase (DNA) II 
beta
Transcription; DNA 
replication; chromatin 
remodelling
5.2 36.5 0.047338493
DNTTIP2 Deoxynucleotidyltrans-
ferase terminal interacting 
protein 2
Transcription; chromatin 
remodelling
4.6 23.9 0.037307658
SCAF11 SR-related CTD associated 
factor 11
RNA splicing 4.5 22.2 0.000497072
SNIP1 Smad nuclear interacting 
protein 1
Transcription Mutations cause PMRED 
(psychomotor retardation, 
epilepsy, and craniofacial 
dysmorphism)
4.3 19.4 0.024277978
UPF3B UPF3B, regulator of non-
sense mediated mRNA 
decay
mRNA surveillance; non-
sense mediated decay
Mutations in XLID 
(X-linked intellectual 
disability) with autism, 
ADHD and scizophrenia
4.2 18.0 0.007231004
FAM98B Family with sequence simi-
larity 98 member B
RNA transport 3.6 12.3 0.00373743
PAK1IP1 PAK1 interacting protein 1 Ribosomal stress response Mutated in mouse model of 
orofacial clefting
3.0 8.2 0.011385542
SS18 SS18, nBAF chromatin 
remodelling complex 
subunit
Transcription Chromosomal translocation 
causes synovial sarcoma
2.3 5.1 0.019649035
YTHDC1 YTH domain containing 1 RNA splicing 2.0 3.9 0.006920967
RNPS1 RNA binding protein with 
serine rich domain 1
RNA transport; nonsense 
mediated decay
1.6 3.0 0.040180758
FTSJ3 FTSJ3 rRNA processing 1.4 2.7 0.04653522
FIP1L1 Factor interacting with 
PAPOLA and CPSF1
RNA polyadenylation Interstitial chromosomal 
deletion results in fusion 
to the PDGFRA gene 
in chronic eosinophilic 
leukaemia
1.2 2.3 0.002115712
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was a difference in step size between wild type, Ostf1LacZ/+ 
and Ostf1LacZ/LacZ. Analysis of the movies did not reveal any 
difference between cohorts: all animals had regular syn-
chronic gait and normal step size, (Fig. 11g).
Ostf1 is expressed in the hippocampus and the mam-
millary bodies, which are thought to be involved in olfac-
tory memory (Yokosuka et al. 1999). We tested our mice 
for olfaction defects by habituating them to chocolate then 
introduced them to a clean cage where chocolate was hid-
den under bedding (Yang and Crawley 2009). Mice were 
timed to find the chocolate up to a maximum of 10 min. 
No difference between cohorts was observed in these tests 
(Fig. 11h).
Since there is significant expression of Ostf1 in the 
inner ear epithelium and in the cochlear ganglion (Fig. 2p) 
mice were examined for signs of auditory defects by test-
ing with a click box. Briefly, a small box produces a loud 
click and causes a flick of the ears [Preyer’s reflex (Jero 
et al. 2001)] and a startle response characterised by neck 
contraction. Similar to the olfaction tests, no difference 
was observed in the auditory response between cohorts 
(Fig. 11i).
Discussion
OSTF1 was previously described as a cytoplasmic protein 
with SH3 and ankyrin domains that indirectly activates 
osteoclast differentiation and regulates their bone-resorbing 
activity (Reddy et al. 1998). OSTF1 was suggested to bind 
to a number of other proteins and previous studies suggested 
functions in spinal motor neuron atrophy and a microde-
letion syndrome (9q21.13) (Baglietto et al. 2014; Boudry-
Labis et al. 2013; Kurihara et al. 2001; Lu et al. 2006; 
Szymkiewicz et al. 2004; Vinayagam et al. 2011). To our 
knowledge, we have generated the first Ostf1 mouse model. 
We show that this is a functional Ostf1 knockout, with LacZ 
placed under control of Ostf1’s regulatory elements. The 
Fig. 11  Ostf1LacZ/LacZ mice behave normally. a No difference is 
observed between wild type, Ostf1+/LacZ and Ostf1LacZ/LacZ mice 
is SHIRPA test. b No difference is observed between wild type, 
Ostf1+/LacZ and Ostf1LacZ/LacZ mice in hang wire latency (WT male 
n = 4, Het male n = 4, KO male n = 8, WT female n = 7, Het female 
n = 7, KO female n = 6). c–f Gait analysis indicate that Ostf1LacZ/LacZ 
walk normally. c Representative flattened timelapse of a mouse walk-
ing through the cat walk box from being placed in the box (left, 
where the gloved hand is) to the relatively darker side where a card-
board tube is (asterisk). Each paw step is labelled with a coloured 
circle (front left, red; front right, yellow; back left, green; back right, 
blue). The three bars, pointed by white arrowheads, are at 10, 20 and 
30 cm each from the side of the box and are used for step calibration. 
d Tracking of each paw as the mouse walks provides a set of coordi-
nates showing that the mouse has walked without pause in a straight 
line. e From these coordinates, step length can be inferred and plotted 
against frame, showing coordination of front left and back right paws 
and front right and back left. f Likewise, step length plotted against 
step indicates that each paw moves regularly. g Average step size in 
millimetre for each animal tested indicate that there is no significant 
difference between genotype. h Mice show no difference in choco-
late burrowing test indicating normal olfaction (n.s. not significant). 
i Mice show no difference in Preyer’s auditory reflex (WT n = 11, Het 
n = 11, KO n = 14, WT vs. Het p > 0.14, WT vs. KO p > 0.25, n.s. not 
significant)
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Ostf1LacZ/LacZ mice were fertile and without overt deleteri-
ous phenotype, at least in the absence of challenge. Sig-
nificantly, none of the phenotypes observed in patients with 
the OSTF1-encompasing microdeletion syndrome were 
observed in either Ostf1LacZ/+ or Ostf1LacZ/LacZ mice, sug-
gesting that heterozygous loss of OSTF1 is not causal of 
the pathogenesis of the syndrome in mice. However, it is 
possible that heterozygous loss of OSTF1 may modify the 
phenotype of loss of other genes within the 9q21.13 locus.
As expected, Ostf1 was found to be expressed in osteo-
clasts. However, while loss of Ostf1 does not impair osteo-
clast differentiation, it has a mild effect on bone architecture 
since both tibia and femur of Ostf1LacZ/LacZ have a higher BV/
TV than normal due to increase in trabecular number, but not 
thickness. Elucidating whether this is an effect on decreased 
osteoclastic activity or increased osteoblastic activity—or 
possibly both- will need to be further investigated. Since 
we and others have shown that OSTF1 interacts with Myo-
sin 1e (which can regulate secretion of CCL2/MIP1) and 
AP3D1 (which regulates peptide hormone release) it will 
be interesting to investigate circulating hormones in Ostf1 
knockout mice.
OSTF1 has been reported to interact with SMN (Kuri-
hara et  al. 2001), a spinal muscular atrophy gene. Like 
SMN, OSTF1 is expressed in osteoclasts and motor neu-
rons. However, we do not find embryonic lethality or rapid 
wastage associated with loss or downregulation of SMN 
(Lefebvre et al. 1997) in the Ostf1 knockouts. Indeed, Ost-
f1lacZ/LacZ behaves normally and live up to 1 year without 
showing signs of muscle wastage. It is, therefore, unclear if 
the OSTF1–SMN interaction originally found by yeast two 
hybrid and pull down of cell lysate (Kurihara et al. 2001) 
occurs in vivo.
Taking advantage of the LacZ cassette, we undertook an 
in-depth analysis of Ostf1 expression in both embryonic and 
adult mice. While various electronic resources are available 
that provide expression analysis, they often lack detailed 
description and are generally limited to tissue level. We 
show here that Ostf1 is expressed widely in multiple organs, 
tissues and cell types, including the brain where Ostf1 
expression was somewhat controversial (Baglietto et al. 
2014; Boudry-Labis et al. 2013). Interestingly, our results 
indicate Ostf1 is widely expressed in the vascular compart-
ment (endothelial cells). However, Ostf1 is not found in all 
blood vessels, and throughout development, suggestive of 
a specialised function in a subset of vessels. Perhaps the 
most striking vascular expression of Ostf1 was observed in 
the specialised vasculature of the liver. It will be interest-
ing to test the functional relevance of this in the future, for 
instance by analysing angiogenesis and/or regeneration fol-
lowing liver damage. More complex still but not less strik-
ing is Ostf1 expression in the kidney, where it was found to 
be distributed to a series of specialised structure including 
the vasculature, the glomeruli and the nephrons. Given that 
unchallenged Ostf1LacZ/LacZ mice do not show and physical 
or histological signs of kidney disease, it will be interest-
ing to challenge this organ too, to elucidate the functional 
relevance of this fascinating distribution.
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